GlassScriptPhysician profile
Sadia M Dar
NPI 1326115577
$1,986.22
in general payments reported to CMS, 2019-2025
38 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $129 · 2021: $179 · 2022: $190 · 2023: $446 · 2024: $469 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $302.07 | 2019-2025 | |
| Amgen INC. | $172.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $166.81 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $155.96 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $138.90 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $121.91 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $102.26 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $93.05 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $80.94 | 2020-2025 | Airsupra |
| Indivior INC. | $78.24 | 2019-2024 | Sublocade |
| Dexcom, INC. | $76.09 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $75.69 | 2019-2025 | Lagevrio |
| Biohaven Pharmaceutical Holding Company LTD. | $48.16 | 2022 | |
| Astellas Pharma US INC | $44.19 | 2025 | Veozah |
| Boston Scientific Corporation | $37.84 | 2023 | Bodyguardian |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.24 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.69 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.94 | 2025 | Jardiance |
| Redhill Biopharma INC. | $18.03 | 2021 | |
| Esperion Therapeutics, INC. | $17.91 | 2024 | Nexletol |
| Phadia US INC. | $17.43 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.76 | 2023 | Seglentis |
| Tris Pharma INC | $16.69 | 2024 | Dyanavel Xr |
| Axonics, INC. | $15.86 | 2021 | |
| Hologic Sales and Service, LLC | $15.41 | 2022 | |
| Cardiovascular Systems INC. | $15.31 | 2020 | |
| Genentech USA, INC. | $15.08 | 2019 | |
| Currax Pharmaceuticals LLC | $14.58 | 2022 | |
| Celgene Corporation | $13.05 | 2019 | |
| Orexo US, INC. | $12.95 | 2019 | |
| Bardy Diagnostics, INC. | $5.00 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.